Results 121 to 130 of about 78,685 (264)

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species

open access: yesJournal of Translational Medicine
Background The lack of a definitive cure for Alzheimer's disease (AD) is fueling the search for innovative therapeutic strategies. Having revolutionized cancer immunotherapy, immune cell engineering with chimeric antigen receptors (CAR) is being explored
Cynthia J. Siebrand   +4 more
doaj   +1 more source

Selenium‐Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers

open access: yesAdvanced Science, EarlyView.
This reivew summarizes Selenium as a multifunctional anticancer regulator in gynecological cancers. It reduces tumor risk, enhances therapeutic efficacy, and reduces treatment toxicity. Selenium also overcomes chemoraditherapy resistance, improving overall treatment outcomes. ABSTRACT Gynecological cancers present significant therapeutic challenges due
Hejing Liu   +9 more
wiley   +1 more source

Application of adoptive cell therapy in malignant melanoma

open access: yesJournal of Translational Medicine
Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to ...
Qianrong Hu   +7 more
doaj   +1 more source

Engineering Chimeric Antigen Receptors Into Homing Missiles [PDF]

open access: yesNeurosurgery, 2018
Kamil W, Nowicki   +2 more
openaire   +2 more sources

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs   +4 more
wiley   +1 more source

A Biomimetic Nanoparticle System Intercepts and Degrades Thrombospondin‐1 to Restore Vascular Homeostasis After Ischemic Injury

open access: yesAdvanced Science, EarlyView.
TAX2‐NPs capture extracellular TSP‐1 in the injured liver and promote its macrophage‐mediated autophagic degradation. This process blocks TSP‐1/CD47 signaling, restores VEGFR2‐AKT activity, preserves endothelial function, and mitigates hepatic ischemia‐reperfusion injury.
Haorui Wang   +12 more
wiley   +1 more source

Scalable Engineering of Bio‐Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient‐Derived Models

open access: yesAdvanced Science, EarlyView.
Engineered extracellular vesicles displaying Ephrin‐B2 selectively target Ephrin‐B4–expressing ovarian cancer cells, enabling precise delivery in patient‐derived models. This scalable bio‐manufacturing platform reveals a versatile strategy to exploit Ephrin signaling for highly specific therapeutic payload delivery and motivates exploration of tailored
Nihar Godbole   +17 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy [PDF]

open access: yesIndian Journal of Medical and Paediatric Oncology, 2020
Azgar Abdul Rasheed   +1 more
openaire   +1 more source

Genetic Code Expanded T Cell for Controllable Immunotherapy

open access: yesAdvanced Science, EarlyView.
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy